Cardlytics Inc (NASDAQ:CDLX) Receives Average Rating of “Buy” from Brokerages

Shares of Cardlytics Inc (NASDAQ:CDLX) have been assigned a consensus rating of “Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $33.67.

A number of analysts recently commented on CDLX shares. KeyCorp boosted their price objective on shares of Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, May 10th. Bank of America reaffirmed a “buy” rating and issued a $32.00 price target (up previously from $22.00) on shares of Cardlytics in a report on Wednesday, July 24th. SunTrust Banks upped their price target on shares of Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. set a $43.00 price target on shares of Cardlytics and gave the company a “buy” rating in a report on Friday, August 9th.

In other news, Director Bryce Youngren sold 174,695 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $33.70, for a total value of $5,887,221.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Polaris Venture Management Co. sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $25.62, for a total transaction of $2,562,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 984,676 shares of company stock valued at $29,041,003. Company insiders own 21.90% of the company’s stock.



Several large investors have recently bought and sold shares of CDLX. Royal Bank of Canada lifted its position in shares of Cardlytics by 166.5% in the 2nd quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock worth $276,000 after buying an additional 6,649 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Cardlytics in the 2nd quarter worth about $1,063,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Cardlytics in the 2nd quarter worth about $277,000. Morgan Stanley increased its holdings in shares of Cardlytics by 760.1% in the 2nd quarter. Morgan Stanley now owns 13,177 shares of the company’s stock worth $342,000 after acquiring an additional 11,645 shares during the period. Finally, UBS Oconnor LLC increased its holdings in shares of Cardlytics by 12.1% in the 2nd quarter. UBS Oconnor LLC now owns 344,354 shares of the company’s stock worth $8,946,000 after acquiring an additional 37,153 shares during the period. 75.09% of the stock is owned by institutional investors and hedge funds.

CDLX stock traded up $0.96 during trading on Friday, reaching $33.37. 473,519 shares of the company were exchanged, compared to its average volume of 424,418. The company has a market cap of $731.48 million, a P/E ratio of -15.59 and a beta of 1.76. Cardlytics has a 52-week low of $9.80 and a 52-week high of $34.64. The stock’s 50 day moving average price is $29.82 and its 200 day moving average price is $21.82. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.01 and a current ratio of 2.01.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.23. The firm had revenue of $48.73 million for the quarter, compared to the consensus estimate of $43.77 million. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The firm’s revenue was up 37.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. As a group, equities research analysts forecast that Cardlytics will post -1.08 EPS for the current year.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Story: What are different types of coverage ratios?

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.